Immunome announces completion of financing by BioAdvance

Immunome, a discovery-stage antibody platform company focused on life-threatening infectious diseases, announced today the completion of a financing by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. The funding round also included private investors.

“The ability to access native human antibodies has been hampered by the lack of a suitable fusion partner and other technical challenges”

"This financing will enable Immunome to identify our first therapeutic candidate for serious infectious diseases utilizing our unparalleled monoclonal antibody technology," said Tim Pelura, president and CEO of Immunome. "Immunome's technology, licensed from MIT and Thomas Jefferson University, enables us to harness the natural curative potential of the human immune system. Based on preliminary work, we believe that the novel antibodies generated by this technology could have unique properties that may provide significant clinical benefit. Immunome is harnessing this technology to develop novel therapies for infections which currently have no or few treatment options."

Infectious diseases remain the third leading cause of death in the United States each year and the second ranking cause of death worldwide according to The World Health Organization. The use of broad-spectrum antibiotics has resulted in the emergence of micro-organisms resistant to multiple therapies (superbugs) and physicians are seeing an increasing number of patients with life threatening infections for which they have limited treatment options.

"The ability to access native human antibodies has been hampered by the lack of a suitable fusion partner and other technical challenges," said Barbara S. Schilberg, managing director and CEO, BioAdvance. "Immunome's technology addresses these challenges and allows capital-efficient identification of antibodies engineered by the human body itself. We look forward to working with this accomplished team to demonstrate the potential of this technology."